Miss Sophia Magwaro BSc, MSc

Institute of Cancer and Genomic Sciences
Trial Management Team Leader

Contact details

Telephone: +44 (0)121 414 3100
Email: s.magwaro@bham.ac.uk

Address: Cancer Research Clinical Trials Unit
Robert Aitken Clinical Research Building
Institute of Cancer and Genomic Sciences
University of Birmingham
Edgbaston
Birmingham B15 2TT

Sophia Magwaro is the A Team (Adult Cancer Trials) Trial Management Team Leader at the Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham.

Qualifications

MSt Genomic Medicine 2021
MSc Clinical Oncology 2010
BSc (Hon) Oncology and Radiotherapy Technology 2003
Health and Care Professions Council registrant

Biography

Sophia Magwaro graduated with a BSc (Hons) Oncology and Radiotherapy Technology from the University of East Anglia. She joined the oncology department at Addenbrookes Hospital as a Treatment Radiographer in 2003 until progressing to the role of Senior I Treatment Planning Radiographer a few years later.

Sophia started working at the Mount Vernon Cancer Centre as a Treatment Radiographer in 2008. She was then appointed as a Radiotherapy Research Radiographer at Imperial College Healthcare NHS Trust (NIHR Cancer Research Network, North West London) in 2009, where she was responsible for the set-up, recruitment and management of phase I - phase III academic and commercial clinical trials. The radiotherapy portfolio covered solid tumours in all cancer disease sites.

Sophia was appointed the A Team, Trial Management Team Leader at the Cancer Research Clinical Trials Unit in September 2019.

Research

Clinical Trials: Urology, Gynaecology, Sarcoma, Lung, Hepatobiliary, Gastrointestinal, Skin, COVID 19

Publications

Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA
Douglas G.Ward, Laura Baxter, Sascha Ott, Naheema S. Gordon, Junhui Wang, Prashant Patel, Kim Piechocki, Lee Silcock, Chris Sale, Maurice P.Zeegers, K.K.Cheng, Nicholas D.James, Richard T.Bryan, BladderPath Trial Management Group (A. Knight, J. Gallagher, S. Magwaro, A. Hughes, A. Pope, N. Tunariu, H. Doyle, Wenyu Liu, H. Mintz, V. Nanton, K. James, S. Hafeez, J.W.F. Catto, K. Jefferson, and S.J. Pirrie). European Urology Oncology (April 2022), https://doi.org/10.1016/j.euo.2022.03.005

Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE Trial
Kearns, Pamela; Siebert, Stefan; Willicombe, Michelle; Gaskell, Charlotte,; Kirkham, Amanda; ; Pirrie, Sarah; ; Bowden, Sarah; Magwaro, Sophia; Hughes, Ana; Lim, Zixiang; Dimitriadis, Stavros; Murray, Sam; Marjot, Thomas; Win, Zay; Irwin, Sophie; Meacham, Georgina; Richter, Alex; Kelleher, Peter; Satsangi, Jack; Miller, Paul; Rea, Daniel; Cook, Gordon;Turtle, Lance; Klenerman, Paul; Dunachie, Susanna; Basu, Neil; de Silva, Thushan; Thomas, David; Barnes, Eleanor; Goodyear, Carl; McInnes, Iain. Lancet pre-print 2021 SSRN: https://ssrn.com/abstract=3910058 or http://dx.doi.org/10.2139/ssrn.3910058

How consistent is breast boost radiotherapy practice across the United Kingdom? Sophia Magwaro. J Radiotherapy Practice 2017 Mar, 16(1): 13-19